Cargando…

Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates

The importance of the organic cation transporter OCT2 in the renal excretion of cationic drugs raises the possibility of drug-drug interactions (DDIs) in which an inhibitor (perpetrator) drug decreases OCT2-dependent renal clearance of a victim (substrate) drug. In fact, there are clinically signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hacker, Kristina, Maas, Renke, Kornhuber, Johannes, Fromm, Martin F., Zolk, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556614/
https://www.ncbi.nlm.nih.gov/pubmed/26327616
http://dx.doi.org/10.1371/journal.pone.0136451
_version_ 1782388363474501632
author Hacker, Kristina
Maas, Renke
Kornhuber, Johannes
Fromm, Martin F.
Zolk, Oliver
author_facet Hacker, Kristina
Maas, Renke
Kornhuber, Johannes
Fromm, Martin F.
Zolk, Oliver
author_sort Hacker, Kristina
collection PubMed
description The importance of the organic cation transporter OCT2 in the renal excretion of cationic drugs raises the possibility of drug-drug interactions (DDIs) in which an inhibitor (perpetrator) drug decreases OCT2-dependent renal clearance of a victim (substrate) drug. In fact, there are clinically significant interactions for drugs that are known substrates of OCT2 such as metformin. To identify drugs as inhibitors for OCT2, individual drugs or entire drug libraries have been investigated in vitro by using experimental probe substrates such as 1-methyl-4-phenylpyridinium (MPP(+)) or 4–4-dimethylaminostyryl-N-methylpyridinium (ASP(+)). It has been questioned whether the inhibition data obtained with an experimental probe substrate such as MPP(+) or ASP(+) might be used to predict the inhibition against other, clinical relevant substrates such as metformin. Here we compared the OCT2 inhibition profile data for the substrates metformin, MPP(+) and ASP(+). We used human embryonic kidney (HEK 293) cells stably overexpressing human OCT2 as the test system to screen 125 frequently prescribed drugs as inhibitors of OCT2-mediated metformin and MPP(+) uptake. Data on inhibition of OCT2-mediated ASP(+) uptake were obtained from previous literature. A moderate correlation between the inhibition of OCT2-mediated MPP(+), ASP(+), and metformin uptake was observed (pairwise r (s) between 0.27 and 0.48, all P < 0.05). Of note, the correlation in the inhibition profile between structurally similar substrates such as MPP(+) and ASP(+) (Tanimoto similarity T = 0.28) was even lower (r (s) = 0.27) than the correlation between structurally distinct substrates, such as ASP(+) and metformin (T = 0.01; r (s) = 0.48) or MPP(+) and metformin (T = 0.01; r (s) = 0.40). We identified selective as well as universal OCT2 inhibitors, which inhibited transport by more than 50% of one substrate only or of all substrates, respectively. Our data suggest that the predictive value for drug-drug interactions using experimental substrates rather than the specific victim drug is limited.
format Online
Article
Text
id pubmed-4556614
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45566142015-09-10 Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates Hacker, Kristina Maas, Renke Kornhuber, Johannes Fromm, Martin F. Zolk, Oliver PLoS One Research Article The importance of the organic cation transporter OCT2 in the renal excretion of cationic drugs raises the possibility of drug-drug interactions (DDIs) in which an inhibitor (perpetrator) drug decreases OCT2-dependent renal clearance of a victim (substrate) drug. In fact, there are clinically significant interactions for drugs that are known substrates of OCT2 such as metformin. To identify drugs as inhibitors for OCT2, individual drugs or entire drug libraries have been investigated in vitro by using experimental probe substrates such as 1-methyl-4-phenylpyridinium (MPP(+)) or 4–4-dimethylaminostyryl-N-methylpyridinium (ASP(+)). It has been questioned whether the inhibition data obtained with an experimental probe substrate such as MPP(+) or ASP(+) might be used to predict the inhibition against other, clinical relevant substrates such as metformin. Here we compared the OCT2 inhibition profile data for the substrates metformin, MPP(+) and ASP(+). We used human embryonic kidney (HEK 293) cells stably overexpressing human OCT2 as the test system to screen 125 frequently prescribed drugs as inhibitors of OCT2-mediated metformin and MPP(+) uptake. Data on inhibition of OCT2-mediated ASP(+) uptake were obtained from previous literature. A moderate correlation between the inhibition of OCT2-mediated MPP(+), ASP(+), and metformin uptake was observed (pairwise r (s) between 0.27 and 0.48, all P < 0.05). Of note, the correlation in the inhibition profile between structurally similar substrates such as MPP(+) and ASP(+) (Tanimoto similarity T = 0.28) was even lower (r (s) = 0.27) than the correlation between structurally distinct substrates, such as ASP(+) and metformin (T = 0.01; r (s) = 0.48) or MPP(+) and metformin (T = 0.01; r (s) = 0.40). We identified selective as well as universal OCT2 inhibitors, which inhibited transport by more than 50% of one substrate only or of all substrates, respectively. Our data suggest that the predictive value for drug-drug interactions using experimental substrates rather than the specific victim drug is limited. Public Library of Science 2015-09-01 /pmc/articles/PMC4556614/ /pubmed/26327616 http://dx.doi.org/10.1371/journal.pone.0136451 Text en © 2015 Hacker et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hacker, Kristina
Maas, Renke
Kornhuber, Johannes
Fromm, Martin F.
Zolk, Oliver
Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title_full Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title_fullStr Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title_full_unstemmed Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title_short Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
title_sort substrate-dependent inhibition of the human organic cation transporter oct2: a comparison of metformin with experimental substrates
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556614/
https://www.ncbi.nlm.nih.gov/pubmed/26327616
http://dx.doi.org/10.1371/journal.pone.0136451
work_keys_str_mv AT hackerkristina substratedependentinhibitionofthehumanorganiccationtransporteroct2acomparisonofmetforminwithexperimentalsubstrates
AT maasrenke substratedependentinhibitionofthehumanorganiccationtransporteroct2acomparisonofmetforminwithexperimentalsubstrates
AT kornhuberjohannes substratedependentinhibitionofthehumanorganiccationtransporteroct2acomparisonofmetforminwithexperimentalsubstrates
AT frommmartinf substratedependentinhibitionofthehumanorganiccationtransporteroct2acomparisonofmetforminwithexperimentalsubstrates
AT zolkoliver substratedependentinhibitionofthehumanorganiccationtransporteroct2acomparisonofmetforminwithexperimentalsubstrates